Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

676
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
676
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.3K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.3K
T Cell Types and Functions01:24

T Cell Types and Functions

3.3K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
3.3K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

758
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
758
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

947
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
947
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

644
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
644

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A modified Delphi consensus on tenosynovial giant cell tumour and giant cell tumour of bone : a report from the Birmingham Orthopaedic Oncology Meeting (BOOM).

The bone & joint journal·2026
Same author

Complications of PI to PIII hemipelvic resections for intermediate and malignant tumours : a systematic review and meta-analysis.

Bone & joint open·2026
Same author

Sex-Related Effects on the Clinical Presentation of Uveitis.

American journal of ophthalmology·2026
Same author

Shelf acetabuloplasty in children diagnosed with osteonecrosis of the femoral head secondary to acute lymphoblastic leukaemia.

BMC musculoskeletal disorders·2025
Same author

Nano-Encapsulated Cumin Oil and <i>Bacillus subtilis</i> Enhance Growth Performance, Immunity, Oxidative Stability, and Intestinal Integrity in Growing Rabbits Under High Ambient Temperature.

Veterinary sciences·2025
Same author

Butyric, lactic, and propionic acids with their salts as natural growth promoters in broilers.

Scientific reports·2025
Same journal

Erratum.

Developments in ophthalmology·2021
Same journal

Pediatric Vitreoretinal Surgery and Integrated Intraoperative Optical Coherence Tomography.

Developments in ophthalmology·2021
Same journal

Integrated Intraoperative Optical Coherence Tomography for Pediatric Lamellar Corneal Transplant Surgery.

Developments in ophthalmology·2021
Same journal

The Use of Optical Coherence Tomography as an Intraoperative Adjunct of Oculoplastic Surgery.

Developments in ophthalmology·2021
Same journal

Integrated Intraoperative Optical Coherence Tomography in Strabismus Surgery.

Developments in ophthalmology·2021
Same journal

Use of Integrated Intraoperative Ocular Coherence Tomography in Pediatric Cataract Surgery: Thinking outside the Box.

Developments in ophthalmology·2021
See all related articles

Related Experiment Video

Updated: Mar 31, 2026

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
07:40

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

6.4K

Immunomodulatory Therapy in Uveitis.

Oren Tomkins-Netzer, Lazha Talat, Filis Ismetova

    Developments in Ophthalmology
    |October 27, 2015
    PubMed
    Summary
    This summary is machine-generated.

    Corticosteroids are primary for intraocular inflammation but can be insufficient or cause side effects. Immunosuppressive drugs help manage ocular inflammation and reduce corticosteroid risks.

    More Related Videos

    Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis
    10:33

    Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis

    Published on: December 17, 2021

    3.3K
    In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
    08:02

    In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

    Published on: January 22, 2020

    6.0K

    Related Experiment Videos

    Last Updated: Mar 31, 2026

    Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
    07:40

    Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

    Published on: January 12, 2022

    6.4K
    Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis
    10:33

    Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis

    Published on: December 17, 2021

    3.3K
    In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
    08:02

    In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

    Published on: January 22, 2020

    6.0K

    Area of Science:

    • Ophthalmology
    • Immunology

    Background:

    • Intraocular inflammation requires treatment, often with corticosteroids.
    • Corticosteroids may be inadequate or lead to adverse effects, limiting long-term use.

    Purpose of the Study:

    • To review immunosuppressive drug classes for ocular inflammation.
    • To discuss their efficacy in augmenting corticosteroid therapy.

    Main Methods:

    • Literature review of immunosuppressive agents.
    • Analysis of their role in managing intraocular inflammation.

    Main Results:

    • Immunosuppressive drugs can enhance corticosteroid effectiveness.
    • They enable reduction of corticosteroid dosage, mitigating side effects.

    Conclusions:

    • Immunosuppressive therapy is crucial for refractory or corticosteroid-intolerant ocular inflammation.
    • These agents offer a viable strategy for sustained disease control.